Ignite Creation Date:
2025-12-24 @ 10:54 PM
Ignite Modification Date:
2025-12-25 @ 8:22 PM
Study NCT ID:
NCT07282769
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-17
First Post:
2025-12-05
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Semaglutide (Wegovy) Treatment for Trichotillomania
Sponsor:
University of Chicago
Organization:
Study Overview
Official Title:
Once Weekly Semaglutide Treatment of Trichotillomania: An Open-Label Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.
Detailed Description:
The goal of the proposed study is to evaluate the efficacy and safety of semaglutide in individuals with trichotillomania. The hypothesis to be tested is that semaglutide will reduce urges to pull hair and pulling behavior and will be well tolerated in participants with trichotillomania. The proposed study will provide needed pilot data on the treatment of a disabling disorder that currently lacks available options for pharmacological treatment.
The investigators will conduct an open-label pharmacotherapy trial in 10 individuals with trichotillomania. Participants with trichotillomania will be started and continued on medication during an 8-week treatment phase. The study will be the first to use a once weekly Glucagon-like peptide 1 (GLP-1) receptor agonist pharmacological intervention to target urges in trichotillomania and thereby has the potential to set a new standard of care for a range of compulsive behaviors.
The investigators will conduct an open-label pharmacotherapy trial in 10 individuals with trichotillomania. Participants with trichotillomania will be started and continued on medication during an 8-week treatment phase. The study will be the first to use a once weekly Glucagon-like peptide 1 (GLP-1) receptor agonist pharmacological intervention to target urges in trichotillomania and thereby has the potential to set a new standard of care for a range of compulsive behaviors.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: